Mobile

A trial comparing efficacy and safety of insulin degludec/insulin aspart and BIAsp 30 in insulin naïve subjects with type 2 diabetes

Mise à jour : Il y a 4 ans
Référence : U1111-1120-5633

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To confirm the efficacy of IDegAsp twice daily (BID) added to metformin in controlling glycaemia with respect to change from baseline in HbA1c after 26 weeks of treatment. This is done by comparing the difference in change from baseline in HbA1c after 26 weeks of treatment between IDegAsp and BIAsp 30 both BID added to metformin, to a non-inferiority limit of 0.4%, and if noninferiority is confirmed, to a superiority limit of 0%.

Critère d'inclusion

  • Type 2 diabetes mellitus

Liens